Revvity Sets Long-Range Targets at Investor Day: 6-8% Organic Growth, 75bps Annual Margin Expansion
RVTY sits 93% above its 52-week low of $81.22.
Summary
At its 2026 Investor Day, Revvity laid out a long-range plan of 6-8% organic growth, 75bps annual margin expansion and double-digit adjusted EPS growth, with ~$5B of capital capacity through 2031. Formal 2027 guidance comes on the Q4 call.
Key Events · Earnings and Guidance · RVTY
-
Long-Range Plan Targets Disclosed
Revvity set an LRP of 6-8% organic revenue growth (~200bps above market), 75bps annual adjusted operating margin expansion and double-digit adjusted EPS growth.
-
Segment Growth Targets
Signals Software is targeted at 10-12% APV growth and Immunodiagnostics at 7-9%, versus 6-8% for Life Sciences Solutions and 3-5% for Reproductive Health; total Diagnostics 5-7% and total Life Sciences 7-9%.
-
2027 Framework and Guidance Timing
Management framed 2027 at ~6% organic growth, ~20bps incremental margin expansion, net interest of ~$85M, a ~19% tax rate and a flat share count; formal 2027 guidance will be given on the Q4 earnings call.
-
Capital Deployment Capacity
Revvity cited ~$5B of capital capacity through 2031, directed at targeted M&A, consistent share repurchases and maintaining the existing dividend, with a commitment to an investment-grade credit rating.
Analysis · RVTY · Industrial Applications And Services
Revvity used its 2026 Investor Day to publish a formal long-range plan for the first time, and the numbers are the story: 6-8% organic revenue growth (roughly 200bps above its end markets), 75bps of annual adjusted operating margin expansion, and double-digit adjusted EPS growth. Segment targets put the fastest growth in Signals Software at 10-12% APV and Immunodiagnostics at 7-9%, while Reproductive Health lags at 3-5%. Management also framed 2027 at ~6% organic growth with a flat share count and ~$85M net interest, and pointed to ~$5B of capital capacity through 2031 for M&A, buybacks and the existing dividend. This is a multi-year commitment rather than a quarterly update, so it resets the bar investors will hold the company to; the formal 2027 guidance arrives on the Q4 earnings call.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RVTY was trading at $157.03 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $17.5B. The 52-week trading range was $81.22 to $171.74. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.